What is the outlook for the CSL (ASX:CSL) share price?

Where to next for CSL shares?

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has had an…. interesting few years. Since topping out at its all-time high of nearly $343 a share back in February 2020, CSL shares have more or less treaded water ever since.

At yesterday's closing share price of $290.13 a share, CSL is 'only' up 1.8% in 2020 so far. That doesn't look great against the broader S&P/ASX 200 Index (ASX: XJO), which has managed a far healthier 9.34% in 2021. CSL is also up a very muted 2.6% over the past 12 months. Again this doesn't compare too favourably against the ASX 200, which is up more than 20% over the same period.

This might come as a surprise to many investors. Prior to 2020, CSL was known as a red hot, but still blue chip, growth share. It managed gains of roughly 50% in 2019, more than 30% in 2018 and around 40% in 2017. So a retreat into single-digit numbers is certainly a sea change for this healthcare company. As is its withdrawal into market-trailing returns.

CSL had a rough time with the outbreak of the pandemic last year. It's experienced issues with its blood plasma collections for one. It also had a potential vaccine candidate, developed in partnership with the University of Queensland, shelved last year.

But where to now for the CSL share price?

Is the CSL share price a buy today?

One broker who thinks there might be some small upside left in CSL shares is investment bank Goldman Sachs. Goldman currently has a 12-month share price target of $305 for CSL. Albeit with the caveat of a current 'neutral' rating.

The broker notes the ongoing sluggishness of CSL's plasma collection business, as well as what it sees as "consecutive years of single-digit earnings growth" as the primary reasons behind this rating.

Goldman reckons there is "a long road to recovery" for the company's plasma collections, which remain well below pre-COVID levels. Further, the bank is concerned that low earnings growth rates are not accurately reflected in the current CSL share price.

Even so, if Goldman's share price prediction proves accurate, it implies a potential upside of 5.1% over the next 12 months.

My Fool colleague James recently discussed the predictions of two other brokers recently. He noted that both Citi and Credit Suisse had slightly higher share price targets on CSL right now, both at $310 a share.

At the current CSL share price, the company has a market capitalisation of $132.05 billion. It also has a price-to-earnings (P/E) ratio of 36.8, and a trailing dividend yield of 0.97%.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Earnings Results

Guess which ASX 100 share is sinking despite record results

This healthcare stock had a record half. Here's what drove its growth.

Read more »

A group of men in the office celebrate after winning big.
Healthcare Shares

Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

Read more »

A young office worker is surrounded by peers who are clapping and congratulating her.
Healthcare Shares

Up 140% in 2024, here's why this ASX 200 healthcare stock is making news again today

It’s yet another positive update for this stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »